Re: Wells Fargo analyst Yanan Zhu maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Ove
Wedbush at $5, Wells at $20, another says buy under $20 for $30, another says $low target = $3, target = $12 and potential of $45. Thanks for the effort analysts.
I'm sticking with $15 pt at some point (12-24 months or in a sale if sooner) assuming they make the right decisions- partner at major value inflection points or as needed for outside scientific, clinical trial or commercial expertise and for goodness sake, don't try to commercialize anything.